Genenta Science CMO Resigns
Ticker: GNTA · Form: 6-K · Filed: Oct 3, 2025 · CIK: 1838716
| Field | Detail |
|---|---|
| Company | Genenta Science S.P.A. (GNTA) |
| Form Type | 6-K |
| Filed Date | Oct 3, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-departure, personnel-change
TL;DR
Genenta Science CMO Carlo Russo is out Oct 31.
AI Summary
On September 30, 2025, Carlo Russo, MD, notified Genenta Science S.p.A. of his resignation as Chief Medical Officer. His resignation is effective October 31, 2025. The company's registration statement on Form F-3 (File No. 333-271901) incorporates this Form 6-K report by reference.
Why It Matters
The departure of a Chief Medical Officer can signal changes in the company's strategic direction or clinical development plans.
Risk Assessment
Risk Level: medium — The resignation of a key executive like the Chief Medical Officer can create uncertainty regarding the company's future clinical development and regulatory strategies.
Key Players & Entities
- Genenta Science S.p.A. (company) — Registrant
- Carlo Russo, MD (person) — Chief Medical Officer resigning
- October 31, 2025 (date) — Effective date of resignation
- September 30, 2025 (date) — Date of notification of resignation
- Form F-3 (File No. 333-271901) (document) — Registration statement incorporating this report
FAQ
Who is resigning from Genenta Science S.p.A. and what is their role?
Carlo Russo, MD, is resigning from his role as Chief Medical Officer.
When is Carlo Russo, MD's resignation effective?
His resignation is effective October 31, 2025.
When was the resignation notified to the company?
The notification of resignation was made on September 30, 2025.
What is the file number for Genenta Science S.p.A.'s registration statement on Form F-3?
The file number is 333-271901.
Does this Form 6-K filing relate to any other SEC filings?
Yes, this Form 6-K report is incorporated by reference into the registrant's registration statement on Form F-3 (File No. 333-271901).
Filing Stats: 477 words · 2 min read · ~2 pages · Grade level 10.2 · Accepted 2025-10-03 16:05:22
Filing Documents
- form6-k.htm (6-K) — 17KB
- 0001493152-25-016847.txt ( ) — 18KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GENENTA SCIENCE S.P.A. By: /s/ Richard B. Slansky Name: Richard B. Slansky Title: Chief Financial Officer Dated: October 3, 2025